The macrophage activation syndrome market is experiencing steady growth, driven by broadened treatment options, improved survival outcomes, and the launch of emerging therapies such as targeting SIRP-α/β1/γ (ELA026), targeting Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)...
2026 Copyright © News-Matic.com. All Rights Reserved
